Tag: Roche

Study of Roche’s Tecentriq plus Platinum-Based Chemotherapy Met its Endpoint

roche
Roche announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival. The combination of Tecentriq® (atezolizumab) plus platinum-based ...

Sanofi Acquired from Roche Exclusive OTC Rights to Tamiflu® in the U.S.

Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu® for the prevention and treatment of influenza or flu in the US. Under the terms of the agreement, San...

Expanded Roche’s Global Access Program Now Includes MTB, HPV, Hepatitis B and C

Roche announced the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle incom...

Immuno-Oncology Imaging Company in Collaboration with Roche

roche
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of the agreeme...

Roche Extends Deadline for Acquisition of Spark Therapeutics by Three Months

Roche disclosed Monday in a filing with the US Securities and Exchange Commission that it will extend the deadline for closing its $4.3-billion acquisition of Spark Therapeutics by three months. Roche...

Primary Endpoint in Phase III Children Study Achived by Roche’s Flu Drug

Roche’s flu drug Xofluza (baloxavir marboxil) has achieved primary endpoint in phase III Ministone-2 children study. The study has showed that Xofluza was well tolerated in children with flu. It al...

CHMP Recommended Roche’s Tecentriq for Treatment of Metastatic Triple-Negative Breast Cancer

Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane®;...

Roche’s Personalised Medicine Rozlytrek Approved in Japan

roche
Roche announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients with neurotrophic tyrosine receptor ...

Roche’s Polivy Granted FDA Accelerated Approval Status

Roche announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) fo...

Roche to Submit Xofluza Flu Prevention Data with Global Health Authorities

clinical-trials
Roche announced that the phase III BLOCKSTONE study, conducted by Shionogi & Co., Ltd., met its primary endpoint showing that people exposed to a household member with influenza (flu) and treated ...

Roche Presents Data from Across Its Breast Cancer Portfolio

Roche presents new and updated results from a number of abstracts highlighting studies including the treatment of both PD-L1-positive triple-negative and HER2-positive breast cancer at the 2019 ASCO A...

Roche and GE Healthcare Establish NAVIFY Tumor Board 2.0

Roche announced the release of NAVIFY Tumor Board 2.0, the first collaboration product from partnership with GE Healthcare. Incorporating medical image viewing and storage capabilities with other pati...

Genentech and Parvus in Worldwide Collaboration

Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, has entered i...

Roche Spins Out New Biotech Nimble Therapeutics

Roche has spun out Nimble Therapeutics, a new biotech that starts life with $10 million in financing and chemical synthesis technology developed at Roche, along with the team that helped create it. Fi...

Ex-Roche Chen Appointed New Everest Medicines CCO

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China ...

Roche and Genentech’s Ocrevus Won a Recommendation from England’s NICE

Patients with Multiple Sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by...